Pneumomediastinum is an uncommon complication of acute respiratory distress syndrome (ARDS) from viral infections, including severe acute respiratory syndrome coronavirus 1 (1). Barotrauma from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (i.e., coronavirus disease [COVID-19]) has been increasingly described (2, 3).We report five patients with pneumomediastinum of 92 critically ill, mechanically ventilated adults with ARDS from COVID-19 at our institution from March 1, 2020, through August 31, 2020 (Figure 1). Unlike other reports (4, 5), no patient had pneumothorax or required tube thoracostomy at diagnosis, suggesting alveolar rupture occurred without disruption of visceral pleura. Pneumomediastinum developed between 24 hours before and 9 days after initiation of mechanical ventilation without evidence of tracheal injury or the use of recruitment maneuvers. Patients received low-Vt ventilation targeting plateau pressures <30 cm H2O to minimize driving pressure, with sedation and/or paralysis used to reduce initial high respiratory effort and limit dyssynchrony. Our cumulative incidence (5.4%) of pneumomediastinum without pneumothorax falls between incidences reported in other series (2, 3). All patients later developed other barotrauma days after initial diagnosis, including two patients who developed pneumopericardium and one who developed pneumoperitoneum with severe subcutaneous emphysema from the neck to the pelvis (Figure 2). Four of the five patientsdied during hospitalization, with the remaining patient being discharged alive.
Figure 1.
Chest radiographs from five patients with coronavirus disease (COVID-19) acute respiratory distress syndrome who developed pneumomediastinum. (A) A 55-year-old man with pneumomediastinum (arrows) and pneumopericardium. (B) A 58-year-old man with pneumomediastinum and significant pneumopericardium (arrow). (C) A 43-year-old man with extensive subcutaneous emphysema and pneumomediastinum. (D) A 54-year-old man with pneumomediastinum and extensive subcutaneous emphysema notable in right axilla and across right chest wall. (E) A 61-year-old man with pneumomediastinum and significant supraclavicular subcutaneous emphysema (arrows). This patient had evidence of pneumomediastinum 24 hours before endotracheal intubation. L = left.
Figure 2.
Noncontrast computed tomographic chest image of a 54-year-old man with coronavirus disease (COVID-19) acute respiratory distress syndrome (ARDS). Extensive bilateral ground glass opacification and consolidation is present, consistent with his known ARDS. Significant pneumomediastinum is demonstrated in addition to extensive subcutaneous emphysema across the chest, arms, and back. Subcutaneous emphysema in this patient extended cephalad into the neck and caudally to the level of the pelvis and scrotum.
Chest radiographs from five patients with coronavirus disease (COVID-19) acute respiratory distress syndrome who developed pneumomediastinum. (A) A 55-year-old man with pneumomediastinum (arrows) and pneumopericardium. (B) A 58-year-old man with pneumomediastinum and significant pneumopericardium (arrow). (C) A 43-year-old man with extensive subcutaneous emphysema and pneumomediastinum. (D) A 54-year-old man with pneumomediastinum and extensive subcutaneous emphysema notable in right axilla and across right chest wall. (E) A 61-year-old man with pneumomediastinum and significant supraclavicular subcutaneous emphysema (arrows). This patient had evidence of pneumomediastinum 24 hours before endotracheal intubation. L = left.Noncontrast computed tomographic chest image of a 54-year-old man with coronavirus disease (COVID-19) acute respiratory distress syndrome (ARDS). Extensive bilateral ground glass opacification and consolidation is present, consistent with his known ARDS. Significant pneumomediastinum is demonstrated in addition to extensive subcutaneous emphysema across the chest, arms, and back. Subcutaneous emphysema in this patient extended cephalad into the neck and caudally to the level of the pelvis and scrotum.
Authors: C M Chu; Y Y Leung; J Y H Hui; I F N Hung; V L Chan; W S Leung; K I Law; C S Chan; K S Chan; K Y Yuen Journal: Eur Respir J Date: 2004-06 Impact factor: 16.671
Authors: Anthony W Martinelli; Tejas Ingle; Joseph Newman; Iftikhar Nadeem; Karl Jackson; Nicholas D Lane; James Melhorn; Helen E Davies; Anthony J Rostron; Aldrin Adeni; Kevin Conroy; Nick Woznitza; Matthew Matson; Simon E Brill; James Murray; Amar Shah; Revati Naran; Samanjit S Hare; Oliver Collas; Sarah Bigham; Michael Spiro; Margaret M Huang; Beenish Iqbal; Sarah Trenfield; Stephane Ledot; Sujal Desai; Lewis Standing; Judith Babar; Razeen Mahroof; Ian Smith; Kai Lee; Nairi Tchrakian; Stephanie Uys; William Ricketts; Anant R C Patel; Avinash Aujayeb; Maria Kokosi; Alexander J K Wilkinson; Stefan J Marciniak Journal: Eur Respir J Date: 2020-11-19 Impact factor: 16.671
Authors: Gareth Jones; Stephen Aston; Rebecca Nightingale; Joseph Lewis; Katelyn Rhiannon Monsell; Lewis Jones; Christopher Smith; Shantanu Kundu; Helena Bond; Hassan Burhan; Tom Fletcher; Thomas Blanchard; Michael Beadsworth; Peter Hampshire; Manish Gautam; Stacy Todd Journal: BMJ Open Respir Res Date: 2021-09
Authors: Alessandro Belletti; Gabriele Todaro; Gabriele Valsecchi; Rosario Losiggio; Diego Palumbo; Giovanni Landoni; Alberto Zangrillo Journal: Crit Care Med Date: 2022-03-01 Impact factor: 9.296